Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$46.81 USD

46.81
2,398,056

-0.75 (-1.58%)

Updated Jul 19, 2024 04:00 PM ET

Pre-Market: $47.00 +0.19 (0.41%) 8:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Exact Sciences (EXAS) Witnesses Rising Expenses, Competition

Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.

Exact Sciences (EXAS) to Showcase Favorable Research Outcome

Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.

Is Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) a Strong ETF Right Now?

Smart Beta ETF report for PRFZ

Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.

Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of 0% and 2.01%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of -17.95% and 19.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Q3 Earnings and Revenues Beat Estimates

Techne (TECH) delivered earnings and revenue surprises of 4.35% and 3.77%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up

Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.

ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand

ICON's (ICLR) first-quarter 2024 performance is driven by its efficient service delivery and strong cost control.

Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up

Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.

Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View

Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.

Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View

Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.

Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note

In the latest trading session, Exact Sciences (EXAS) closed at $63.24, marking a -0.46% move from the previous day.

Thermo Fisher (TMO) Q1 Earnings Top Estimates, 2024 View Up

Thermo Fisher's (TMO) first-quarter 2024 revenues register year-over-year growth driven by new product launches.

Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised

Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?

Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.

Here's Why You Should Retain Prestige Consumer (PBH) Stock Now

The robust strength of Prestige Consumer's (PBH) diversified portfolio bodes well for investors.

ICON (ICLR) Gains From New Offerings, Strategic Acquisitions

ICON (ICLR) continues to develop its collaboration and delivery models, invest in technology and enhance its project and program management capabilities.

Why Exact Sciences (EXAS) Dipped More Than Broader Market Today

Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.